Scarica l'app Stockscreener
4.605
7.85%
0.335
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Precedente Chiudi:
$4.27
Aprire:
$4.29
Volume 24 ore:
4.20M
Relative Volume:
0.68
Capitalizzazione di mercato:
$1.38B
Reddito:
$38.03M
Utile/perdita netta:
$-146.40M
Rapporto P/E:
-8.8558
EPS:
-0.52
Flusso di cassa netto:
$-121.38M
1 W Prestazione:
+11.77%
1M Prestazione:
+14.84%
6M Prestazione:
+46.66%
1 anno Prestazione:
+72.47%
Intervallo 1D:
$4.27
$4.7699
Intervallo di 1 settimana:
$3.93
$5.01
Portata 52W:
$1.8906
$5.82
Abcellera Biologics Inc Stock (ABCL) Company Profile
Nome
Abcellera Biologics Inc
Settore
Industria
Telefono
(604) 559-9005
Indirizzo
150 W 4TH AVENUE, VANCOUVER
Confronta ABCL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.605 | 1.34B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.90 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.28 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.63 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
645.00 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Ripresa | Leerink Partners | Outperform |
| 2024-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2024-02-22 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-10-13 | Ripresa | Piper Sandler | Overweight |
| 2023-02-28 | Iniziato | Cowen | Outperform |
| 2022-12-15 | Iniziato | Goldman | Buy |
| 2022-11-16 | Iniziato | Truist | Buy |
| 2021-12-21 | Iniziato | The Benchmark Company | Buy |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-01-05 | Iniziato | BMO Capital Markets | Outperform |
| 2021-01-05 | Iniziato | Berenberg | Buy |
| 2021-01-05 | Iniziato | Credit Suisse | Outperform |
| 2021-01-05 | Iniziato | SVB Leerink | Outperform |
| 2021-01-05 | Iniziato | Stifel | Buy |
Mostra tutto
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera Biologics stock rating maintained at Hold by Benchmark - Investing.com
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript - AOL.com
AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights - TipRanks
AbCellera to Present at Upcoming Investor Conferences in September - AInvest
AbCellera to Participate at Upcoming Investor Conferences in September - The Globe and Mail
Industry Analysts Just Made A Huge Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Revenue Forecasts - Yahoo Finance
AbCellera's Q2 2025 Earnings Call: Unpacking Contradictions in Regulatory Focus, Dosing Strategies, and Market Expansion - AInvest
Will AbCellera Biologics Inc. benefit from seasonalityRocket Stock Alert Service - mustnews.co.kr
AbCellera Biologics Advances Clinical Trials and Revenue Growth - TipRanks
AbCellera reports Q2 EPS (12c), consensus (16c) - MSN
AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Call Transcript - Insider Monkey
AbCellera Biologics 2025 Q2 Earnings Net Loss Narrows Slightly - AInvest
AbCellera Biologics Reports Q2 2025 Financial Results - The Globe and Mail
AbCellera Biologics Soars 19.34% on Q2 Revenue Surge - AInvest
AbCellera Biologics Inc. shares rise 15.80% premarket after reporting Q2 revenue beat estimates and beginning Phase 1 clinical trial for ABCL635. - AInvest
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... - Yahoo Finance
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... By GuruFocus - Investing.com Canada
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - BioSpace
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating - TipRanks
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Canadian biotech firm AbCellera Q2 revenue beats estimates - MarketScreener
AbCellera soars as revenue more than doubles estimates By Investing.com - Investing.com Australia
Abcellera Biologics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
AbCellera Biologics: A Turning Point in Biotech's Antibody Revolution - AInvest
AbCellera begins dosing in phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
Earnings Flash (ABCL) AbCellera Biologics Inc. Reports Q2 Revenue $17.1M - MarketScreener
Senseonics Holdings Inc Q2 Revenue Reaches $6.6 Million, EPS Loss at $0.02, Meets Analyst Expectations - AInvest
Is AbCellera Biologics Inc. stock overvalued or undervaluedOutstanding yields - Jammu Links News
Is AbCellera Biologics Inc. a growth stock or a value stockInvest confidently with professional market insights - Jammu Links News
What are AbCellera Biologics Inc. company’s key revenue driversOver 200% growth - Jammu Links News
What is the risk reward ratio of investing in AbCellera Biologics Inc. stockFree Stock Chart Pattern Guide - Jammu Links News
Why is AbCellera Biologics Inc. stock attracting strong analyst attentionMarket-beating returns - Jammu Links News
What is the dividend policy of AbCellera Biologics Inc. stockConsistently superior profits - Jammu Links News
How volatile is AbCellera Biologics Inc. stock compared to the marketBuild a diversified portfolio for risk management - Jammu Links News
How many analysts rate AbCellera Biologics Inc. as a “Buy”Achieve breakthrough financial results - Jammu Links News
How does AbCellera Biologics Inc. generate profit in a changing economySuperior profit margins - Jammu Links News
What drives AbCellera Biologics Inc. stock priceMarket-leading growth rates - Jammu Links News
Does AbCellera Biologics Inc. stock perform well during market downturnsAchieve explosive financial results today - Jammu Links News
Is AbCellera Biologics Inc. a good long term investmentInvest smarter with daily trading signals - Jammu Links News
What analysts say about AbCellera Biologics Inc. stockInvest confidently with professional market insights - Jammu Links News
When is AbCellera Biologics Inc. stock expected to show significant growthAchieve rapid financial growth with smart picks - Jammu Links News
Should I hold or sell AbCellera Biologics Inc. stock in 2025Capitalize on fast-moving trading opportunities - Jammu Links News
What are the latest earnings results for AbCellera Biologics Inc.Beginner Investor Alerts For Fast Growth - Jammu Links News
Piper Sandler Reiterates a Buy Rating on AbCellera Biologics (ABCL) - MSN
AbCellera Biologics Institutional Ownership: Sensitivity to Trading Actions Amid Market Cap Decline - AInvest
Institutional owners may ignore AbCellera Biologics Inc.'s (NASDAQ:ABCL) recent US$125m market cap decline as longer-term profits stay in the green - Yahoo Finance
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
AbCellera Biologics Inc. (ABCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
Is it the right time to buy AbCellera Biologics Inc. stockAdvanced Screener Report With High Returns - Jammu Links News
Abcellera Biologics Inc Azioni (ABCL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.71%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):